Expanding Diagnostic Portfolio Mirxes is actively building a comprehensive cancer detection portfolio including tests for lung, thyroid, colorectal, breast, liver, and ovarian cancers. This diversification presents opportunities to offer complementary diagnostic solutions and advanced testing platforms to support their product development pipeline and commercialization efforts.

Global Market Reach With operations and distribution networks spanning Southeast Asia, the USA, Japan, China, and multiple countries worldwide, Mirxes is positioned to seek partnerships and sales collaborations with international healthcare providers, laboratories, and hospitals to expand the adoption of their diagnostic tests across diverse markets.

Innovation in At-Home Testing The launch of at-home screening kits like FITRapid and HELICORapid in Thailand indicates a strategic move towards democratizing diagnostics and increasing accessibility. Opportunities exist to promote remote testing solutions and digital health integrations to broaden their user base and penetrate new regions.

Strong Financial Backing Mirxes has secured significant funding through multiple IPOs and investments, accumulating hundreds of millions USD, which signifies stability and a focus on growth. This financial strength creates prospects for sales of high-value diagnostic instruments, lab automation solutions, and ongoing reagent supplies to support expanding testing volumes.

Collaborative Research Leadership Originating from A*STAR and leveraging advanced microRNA detection technology, Mirxes collaborates with top academic and industry partners globally. Potential partnerships with biotech, pharmaceutical, or research organizations can open new channels for co-developing innovative diagnostic assays and clinical solutions.